254 related articles for article (PubMed ID: 6357025)
21. Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres).
Dubois V; Arpin C; Dupart V; Scavelli A; Coulange L; André C; Fischer I; Grobost F; Brochet JP; Lagrange I; Dutilh B; Jullin J; Noury P; Larribet G; Quentin C
J Antimicrob Chemother; 2008 Aug; 62(2):316-23. PubMed ID: 18467306
[TBL] [Abstract][Full Text] [Related]
22. [Combination of exchange transfusion and directed antibiotic therapy in the treatment of severe sepsis. A case of multi-resistant Serratia marcescens sepsis].
Agnese G; Raddo S
Minerva Pediatr; 1978 May; 30(9):753-7. PubMed ID: 351366
[No Abstract] [Full Text] [Related]
23. The role of outer membrane in Serratia marcescens intrinsic resistance to antibiotics.
Sánchez L; Ruiz N; Leranoz S; Viñas M; Puig M
Microbiologia; 1997 Sep; 13(3):315-20. PubMed ID: 9353750
[TBL] [Abstract][Full Text] [Related]
24. Serratia marcescens isolated in 2005 from clinical specimens from patients with diminished immunity.
Młynarczyk A; Młynarczyk G; Pupek J; Bilewska A; Kawecki D; Łuczak M; Gozdowska J; Durlik M; Paczek L; Chmura A; Rowińnski W
Transplant Proc; 2007 Nov; 39(9):2879-82. PubMed ID: 18022007
[TBL] [Abstract][Full Text] [Related]
25. [Beta-lactam resistance in aquatic Enterobacter cloacae strains using phenotypic and genotypic criteria].
Lazăr V; Cernat R; Balotescu C; Cotar A; Coipan E; Cojocaru C
Bacteriol Virusol Parazitol Epidemiol; 2002; 47(3-4):185-91. PubMed ID: 15085610
[TBL] [Abstract][Full Text] [Related]
26. [Clinical aspects of urinary tract infection by Serratia marcescens].
Miyakita H; Kawashima T; Kinoshita H; Kawamura N
Hinyokika Kiyo; 1984 Feb; 30(2):153-8. PubMed ID: 6377857
[TBL] [Abstract][Full Text] [Related]
27. Some properties of Serratia marcescens, Salmonella paratyphi A, and Enterobacter cloacae with non-enzyme-dependent multiple resistance to beta-lactam antibiotics, aminoglycosides, and quinolones.
Dang P; Gutmann L; Quentin C; Williamson R; Collatz E
Rev Infect Dis; 1988; 10(4):899-904. PubMed ID: 3055181
[TBL] [Abstract][Full Text] [Related]
28. Serratia marcescens in a general hospital.
Ball AP; McGhie D; Geddes AM
Q J Med; 1977 Jan; 46(181):63-71. PubMed ID: 325592
[TBL] [Abstract][Full Text] [Related]
29. Comparative susceptibilities of clinical isolates of Serratia marcescens to newer cephalosporins, alone and in combination with various aminoglycosides.
Markowitz SM; Sibilla DJ
Antimicrob Agents Chemother; 1980 Nov; 18(5):651-5. PubMed ID: 7004344
[TBL] [Abstract][Full Text] [Related]
30. Serratia marcescens: use of detailed characterization of strains to evaluate an increase of isolates in an intensive care unit.
Cardos SF; Florman AL; Simberkoff MS; Lanier L
Am J Med Sci; 1973 Dec; 266(6):447-52. PubMed ID: 4590096
[No Abstract] [Full Text] [Related]
31. [Susceptibility of recent clinical isolates of Pseudomonas aeruginosa and Serratia marcescens to cefotaxime, ceftizoxime, cefmenoxime, latamoxef and cefsulodin in comparison with other beta-lactam antibiotics and aminoglycosides].
Kawakami Y; Okimura Y; Horiuchi N; Kanai M
Jpn J Antibiot; 1982 Sep; 35(9):2314-7. PubMed ID: 6292543
[No Abstract] [Full Text] [Related]
32. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia.
Ko WC; Lee HC; Chuang YC; Liu CC; Wu JJ
J Infect; 2000 May; 40(3):267-73. PubMed ID: 10908022
[TBL] [Abstract][Full Text] [Related]
33. The emergence of resistance and the therapy of septicaemia.
Phillips I; Shannon K
Chemioterapia; 1985 Feb; 4(1):90-4. PubMed ID: 3986947
[TBL] [Abstract][Full Text] [Related]
34. [Increasing incidence of Serratia marcescens bacteraemia in intensive care patients (author's transl)].
Lackner F; Coraim F; Benzer H; Koller W; Pichler H; Rotter M; Stanek G
Anaesthesist; 1978 Sep; 27(9):434-8. PubMed ID: 362983
[TBL] [Abstract][Full Text] [Related]
35. In vitro activities of beta-lactam antibiotics alone and in combination with sulbactam against Gram-negative bacteria.
Wang FD; Lin ML; Lee WS; Liu CY
Int J Antimicrob Agents; 2004 Jun; 23(6):590-5. PubMed ID: 15194130
[TBL] [Abstract][Full Text] [Related]
36. The in vivo and in vitro potentiation of sulfamethoxazole by trimethoprim against strains of Serratia marcescens.
Grunberg E; Beskid G; DeLorenzo WF; Cleeland R
Int J Clin Pharmacol; 1973 Aug; 8(1):47-50. PubMed ID: 4580383
[No Abstract] [Full Text] [Related]
37. Bacterial resistance to beta-lactams, and its prevention with combination antimicrobial therapy.
Barriere SL
Pharmacotherapy; 1992; 12(5):397-402. PubMed ID: 1437700
[TBL] [Abstract][Full Text] [Related]
38. Survey of CTX-M-3 extended-spectrum beta-lactamase (ESBL) among cefotaxime-resistant Serratia marcescens at a medical center in middle Taiwan.
Wu LT; Tsou MF; Wu HJ; Chen HE; Chuang YC; Yu WL
Diagn Microbiol Infect Dis; 2004 Jun; 49(2):125-9. PubMed ID: 15183862
[TBL] [Abstract][Full Text] [Related]
39. Appearance of aac(6')-Ib-cr gene among extended-spectrum beta-lactamase-producing Enterobacteriaceae in a French hospital.
Fihman V; Lartigue MF; Jacquier H; Meunier F; Schnepf N; Raskine L; Riahi J; Sanson-le Pors MJ; Berçot B
J Infect; 2008 Jun; 56(6):454-9. PubMed ID: 18440645
[TBL] [Abstract][Full Text] [Related]
40. [Sensitivity of Serratia marcescens to chemotherapy].
Neguţ M; Niţulescu A; Potcoavă R
Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Bacteriol Virusol Parazitol Epidemiol; 1978; 23(1):27-36. PubMed ID: 349661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
